| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Radiology and Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Correspondence: For correspondence and reprints contact: Leena M. Hamberg, PhD, Massachusetts General Hospital, Dept. of Radiology, 13th St., Bldg. 149, Room 2329, Charlestown, MA 02129.
ABSTRACT
The dose uptake ratio (DUR) has been used as a quantitative index of glucose metabolism for tumor classification and monitoring response to treatment. In order to provide consistent results, DUR measurements should be made when the concentration of tracer has reached a plateau. The time of this plateau cannot be identified from a single static acquisition. Methods: In this study, we investigated the changes in DUR as a function of time in eight patients with stage III lung cancer. All patients underwent a quantitative dynamic 18F-FDG PET study before and after treatment and the data were analyzed with a three-compartment model. Using the fitted model parameters, the DUR was predicted at the plateau and intermediate times. Results: Tumor concentrations of 18F-FDG did not reach a plateau within the 90 min of imaging in any of the pre-treatment studies and only in one case post-treatment. The average time to reach 95% of the plateau value pre-treatment was 298 ± 42 min (range: 130–500 min); in post-treatment, it was 154 ± 31 min (range: 65–240 min). The difference between the plateau DUR and the 60-min value was 46% ± 6% pre-treatment and 17% ± 5% post-treatment. Conclusions: These data indicate that DUR can vary widely with the time of measurement and that DUR should be interpreted with caution in any individual patient.
Key Words: PET-FDG • DUR • glucose metabolism • compartmental analysis • lung cancer • diagnostic imaging
This article has been cited by other articles:
|
|
 |
|
  D. Uesaka, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, Y. Fujibayashi, and H. Okazawa Evaluation of Dual-Time-Point 18F-FDG PET for Staging in Patients with Lung Cancer J. Nucl. Med., October 1, 2008; 49(10): 1606 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nomori, T. Mori, K. Ikeda, K. Kawanaka, S. Shiraishi, K. Katahira, and Y. Yamashita Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hellwig, T. P. Graeter, D. Ukena, A. Groeschel, G. W. Sybrecht, H.-J. Schaefers, and C.-M. Kirsch 18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense? J. Nucl. Med., November 1, 2007; 48(11): 1761 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamamoto, T. Z. Wong, T. G. Turkington, T. C. Hawk, and R. E. Coleman Head and Neck Cancer: Dedicated FDG PET/CT Protocol for Detection--Phantom and Initial Clinical Studies Radiology, July 1, 2007; 244(1): 263 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mavi, M. Urhan, J. Q. Yu, H. Zhuang, M. Houseni, T. F. Cermik, D. Thiruvenkatasamy, B. Czerniecki, M. Schnall, and A. Alavi Dual Time Point 18F-FDG PET Imaging Detects Breast Cancer with High Sensitivity and Correlates Well with Histologic Subtypes J. Nucl. Med., September 1, 2006; 47(9): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-i. Watanabe, H. Nomori, T. Ohtsuka, T. Naruke, A. Ebihara, H. Orikasa, K. Yamazaki, K. Uno, T. Kobayashi, and T. Goya [F-18]Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 403 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nomori, N. Kosaka, K. Watanabe, T. Ohtsuka, T. Naruke, T. Kobayashi, and K. Uno 11C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography Ann. Thorac. Surg., December 1, 2005; 80(6): 2020 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kumar, V. A. Loving, A. Chauhan, H. Zhuang, S. Mitchell, and A. Alavi Potential of Dual-Time-Point Imaging to Improve Breast Cancer Diagnosis with 18F-FDG PET J. Nucl. Med., November 1, 2005; 46(11): 1819 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno Visual and Semiquantitative Analyses for F-18 Fluorodeoxyglucose PET Scanning in Pulmonary Nodules 1 cm to 3 cm in Size Ann. Thorac. Surg., March 1, 2005; 79(3): 984 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Salaun, R. K. Grewal, I. Dodamane, H. W. Yeung, S. M. Larson, and H. W. Strauss An Analysis of the 18F-FDG Uptake Pattern in the Stomach J. Nucl. Med., January 1, 2005; 46(1): 48 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Spence, M. Muzi, D. A. Mankoff, S. F. O'Sullivan, J. M. Link, T. K. Lewellen, B. Lewellen, P. Pham, S. Minoshima, K. Swanson, et al. 18F-FDG PET of Gliomas at Delayed Intervals: Improved Distinction Between Tumor and Normal Gray Matter J. Nucl. Med., October 1, 2004; 45(10): 1653 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Thie Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage J. Nucl. Med., September 1, 2004; 45(9): 1431 - 1434. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Sundaram, N. M.T. Freedman, J. A. Carrasquillo, J. M. Carson, M. Whatley, S. K. Libutti, D. Sellers, and S. L. Bacharach Simplified Kinetic Analysis of Tumor 18F-FDG Uptake: A Dynamic Approach J. Nucl. Med., August 1, 2004; 45(8): 1328 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bagheri, A. H. Maurer, L. Cone, M. Doss, and L. Adler Characterization of the Normal Adrenal Gland with 18F-FDG PET/CT J. Nucl. Med., August 1, 2004; 45(8): 1340 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kapoor, B. M. McCook, and F. S. Torok An Introduction to PET-CT Imaging RadioGraphics, March 1, 2004; 24(2): 523 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Beaulieu, P. Kinahan, J. Tseng, L. K. Dunnwald, E. K. Schubert, P. Pham, B. Lewellen, and D. A. Mankoff SUV Varies with Time After Injection in 18F-FDG PET of Breast Cancer: Characterization and Method to Adjust for Time Differences J. Nucl. Med., July 1, 2003; 44(7): 1044 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Demura, T. Tsuchida, T. Ishizaki, S. Mizuno, Y. Totani, S. Ameshima, I. Miyamori, M. Sasaki, and Y. Yonekura 18F-FDG Accumulation with PET for Differentiation Between Benign and Malignant Lesions in the Thorax J. Nucl. Med., April 1, 2003; 44(4): 540 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. de Boer, J. Pruim, B. F.A.M. van der Laan, T. H. Que, A. T.M. Willemsen, F. W.J. Albers, and W. Vaalburg L-1-11C-Tyrosine PET in Patients with Laryngeal Carcinomas: Comparison of Standardized Uptake Value and Protein Synthesis Rate J. Nucl. Med., March 1, 2003; 44(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Matthies, M. Hickeson, A. Cuchiara, and A. Alavi Dual Time Point 18F-FDG PET for the Evaluation of Pulmonary Nodules J. Nucl. Med., July 1, 2002; 43(7): 871 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Zhang, M Tian, N Oriuchi, T Higuchi, S Tanada, and K Endo Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET Br. J. Radiol., May 31, 2002; 75(893): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Pieterman, T. H. Que, P. H. Elsinga, J. Pruim, J. W.G. van Putten, A. T.M. Willemsen, W. Vaalburg, and H. J.M. Groen Comparison of 11C-Choline and 18F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer J. Nucl. Med., February 1, 2002; 43(2): 167 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhuang, M. Pourdehnad, E. S. Lambright, A. J. Yamamoto, M. Lanuti, P. Li, P. D. Mozley, M. D. Rossman, S. M. Albelda, and A. Alavi Dual Time Point 18F-FDG PET Imaging for Differentiating Malignant from Inflammatory Processes J. Nucl. Med., September 1, 2001; 42(9): 1412 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Imdahl, S. Jenkner, I. Brink, E. Nitzsche, E. Stoelben, E. Moser, and J. Hasse Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 324 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Brink, M. J. Reinhardt, S. Hoegerle, C. Altehoefer, E. Moser, and E. U. Nitzsche Increased Metabolic Activity in the Thymus Gland Studied with 18F-FDG PET: Age Dependency and Frequency After Chemotherapy J. Nucl. Med., April 1, 2001; 42(4): 591 - 595. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Thie, K. F. Hubner, and G. T. Smith The Diagnostic Utility of the Lognormal Behavior of PET Standardized Uptake Values in Tumors J. Nucl. Med., October 1, 2000; 41(10): 1664 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Vesselle, R. A. Schmidt, J. M. Pugsley, M. Li, S. G. Kohlmyer, E. Vallières, and D. E. Wood Lung Cancer Proliferation Correlates with [F-18]Fluorodeoxyglucose Uptake by Positron Emission Tomography Clin. Cancer Res., October 1, 2000; 6(10): 3837 - 3844. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. M. Wilmshurst, S. F. Barrington, D. Pritchard, T. Cox, P. Bullock, M. Maisey, and R. O. Robinson Positron Emission Tomography in Imaging Spinal Cord Tumors J Child Neurol, July 1, 2000; 15(7): 465 - 472. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Fukuchi, K. Hayashida, H. Moriwaki, K. Fukushima, N. Kume, T. Katafuchi, M. Sago, M. Takamiya, and Y. Ishida Brain Fluorine-18 Fluorodeoxyglucose Imaging with Dual-Head Coincidence Gamma Camera:Comparison with Dedicated Ring-Detector PositronEmission Tomography AJNR Am. J. Neuroradiol., January 1, 2000; 21(1): 99 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Shreve, Y. Anzai, and R. L. Wahl Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants RadioGraphics, January 1, 1999; 19(1): 61 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al. Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose Blood, June 15, 1998; 91(12): 4464 - 4471. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
